Objective: To determine the effects of antiplatelet therapy among patients at high risk of
occlusive vascular events. Design: Collaborative meta-analyses (systematic overviews) …

Objective: To determine the effects of “prolonged” antiplatelet therapy (that is, given for one
month or more) on “vascular events”(non-fatal myocardial infarctions, non-fatal strokes, or …

The role of aspirin and other platelet-active drugs in the treatment and prevention of
atherothrombosis has been reviewed recently by the Sixth American College of Chest …

OBJECTIVE--To determine the efficacy of antiplatelet therapy in maintaining vascular
patency in various categories of patients. DESIGN--Overviews of 46 randomised trials of …

OBJECTIVE To determine the cardiovascular and coronary risk thresholds at which aspirin
for primary prevention of coronary heart disease is safe and worthwhile. DESIGN Meta …

Low-dose aspirin has been shown to be effective in preventing about one-fifth of
atherothrombotic vascular complications (non-fatal myocardial infarction, non-fatal stroke, or …

Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and
other serious vascular events in patients with a history of previous vascular events or known …

Objective: To determine which groups of patients may derive particular benefit or experience
harm from the use of low dose aspirin for the primary prevention of coronary heart disease …

Antiplatelet therapy, most notably aspirin, has been well documented to reduce risks of
subsequent cardiovascular disease (CVD) in secondary prevention, acute myocardial …

BACKGROUND: Low-dose aspirin is of definite and substantial net benefit for many people
who already have occlusive vascular disease. We have assessed the benefits and risks in …